Loading clinical trials...
Loading clinical trials...
PATROL: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease
This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.
OUTLINE: Participants undergo collection of blood, urine, and/or tissue samples every 6-12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 3-9 months after completion of curative therapy for up to 3 years.
Age
40 - No limit years
Sex
MALE
Healthy Volunteers
Yes
City of Hope
Duarte, California, United States
University of California, San Francisco
San Francisco, California, United States
Northwestern
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
OHSU Knight Cancer Institute
Portland, Oregon, United States
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
May 21, 2020
Primary Completion Date
August 31, 2030
Completion Date
August 31, 2030
Last Updated
November 10, 2025
450
ESTIMATED participants
Biospecimen Collection
PROCEDURE
Laboratory Biomarker Analysis
OTHER
Quality-of-Life Assessment
OTHER
Questionnaire Administration
OTHER
Lead Sponsor
University of Washington
Collaborators
NCT04550494
NCT04857502
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions